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DEVELOPMENT AND CHARACTERIZATION OF MONOCLONAL
ANTIBODIES DIRECTED AGAINST TANAPOX VIRUS
Michael Franz, M.S.
Western Michigan University, 2004
The initial symptoms of a Tanapoxvirus (TPV) infection are
indistinguishable from smallpox, which is caused by variola virus (VV). In the
post-9/11 area, reagents that can quickly differentiate a TPV infection from
smallpox are very desirable, but currently unavailable. Monoclonal antibodies
(mAbs) directed specifically against TPV can be used for this purpose. Six mAbs
were developed and characterized that specifically bind to TPV infected owl
monkey kidney (OMK) cells, but not uninfected cells. The apparent molecular
mass of the TPV protein(s) recognized by 5 mAbs were calculated using the
Western blot technique. One mAb demonstrated no binding using the Western
blot technique, but demonstrated specific binding to TPV protein(s) by ELISA
and indirect immunofluorescence microscopy. Since TPV is included in the
genus Yatapoxvirus and the VV is included in the genus Orthopoxvirus, with no
immunological cross-reactivity, it is presumed that these antibodies will react with
TPV proteins and not VV proteins.
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INTRODUCTION

Tanapoxvirus (TPV) is a large DNA containing virus included in the
family Poxviridae, where it has been classified as a yatapoxvirus. TPV
causes a mild, self-limiting, febrile infection in humans with very few skin
lesions (Downie et al., 1971). Morphologically TPV is very similar to variola
virus (VV), the causative agent of smallpox, and cannot be differentiated from
other poxviruses based on electron microscopy. Smallpox is the most feared
disease of the post-9/11 era. Although TPV infection is endemic to Africa,
recently there was one case in Europe (Stich et al., 2002) and another in the
United States (Dhar et al., 2004) where individuals returning from Africa
showed classical poxvirus symptoms and the virus appeared to be similar in
morphology to VV. It was, therefore, necessary to have essential diagnostic
reagents at hand to rule out smallpox. The TPV genomic sequence data
generated in our laboratory (Neering, 1993; Paulose et al., 1998) were very
useful in confirming a TPV infection and ruling out smallpox.
The purpose of this study was to generate even simpler reagents,
monoclonal antibodies (mAbs), to facilitate simpler, faster and more cost
effective methods to differentiate a TPV infection from a VV infection. Here I
describe the generation and characterization of six anti-TPV monoclonal
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antibodies that can be potentially used for this purpose. These antibodies
specifically recognize TPV antigens. Since VV (an orthropoxvirus) and TPV
(a yatapoxvirus) are antigenically distinct based on immunological cross
reactivity. We believe these mAbs will be very useful to differentiate TPV
from VV. Unfortunately federal law prohibits us from working with VV to
provide evidence for this notion. Perhaps in the near future the Centers for
Disease Control and Prevention (CDC) in Atlanta, one of the two laboratories
in the world with VV, will be able to confirm our findings.
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REVIEW OF LITERATURE

Poxviruses
Poxviruses are among the most complex and perhaps the most
studied of all known animal viruses. A member of the family Poxviridae, VV is
the causative agent of the disease smallpox the most feared disease of all
time. Smallpox was declared eradicated from the face of the globe in1977 as
a result of a rigorous vaccination program and is considered one of the major
achievements of modern science. Fears of bioterrorism in the post 9/11 era
has, however, raised speculation about the intentional release and
reemergence of smallpox in the global population without any specific
immunity to smallpox
Basic research on vaccinia virus (VAC) has greatly pioneered our
understanding of viruses. The eradication of smallpox was achieved through
injections of the closely related vaccinia virus, a poxvirus antigenically similar
to VV, coining the term vaccination. The process of vaccination to prevent
infectious diseases is common practice today, but it was initially pioneered,
over 200 years ago, by Edward Jenner after his observation that milkmaids
who had exposure to cowpox seemed to have immunity against smallpox.
Vaccinia virus was also the first animal virus seen microscopically and
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extensively studied. The discovery that purified VAC contains enzymes that
synthesize mRNA (Kates and Beeson, 1970; Golini and Kates, 1985)
changed the overly simplistic view that viruses are just little bundles of nucleic
acids.

Research on poxviruses has spearheaded our understanding of viral

pathogenesis.

The discovery and study of. viral encoded proteins may

provide new insights into virus/host relationships as well as elucidate the
mechanisms of the host immune system.
All members of Poxviridae are large complex virions containing a
single linear double stranded DNA molecule that may range in size from 130
kbp to 300 kbp, as well as enzymes that synthesize mRNA. Poxviruses go
through two distinct stages of uncoating. The first uncoating process occurs
immediately upon entry into the cytoplasm of the host cell. The second stage
requires proteins produced by the early transcription system contained within
the virus to take place. The enzymes contained within the virus are
responsible for the synthesis of viral mRNA and the processing of that viral
mRNA in a manner that is similar to eukaryotic mRNA. The processed viral
mRNA is capped and methylated (Wei and Moss, 1975). The viral mRNA
also has a poly A tail (Kates and Beeson, 1970). Vacinia virus early mRNA
can be detected in the cytoplasm within 20 minutes of infection and
accumulates to its highest levels within 1-2 hours. The amount of viral mRNA
declines in concentration at a similar rate with measurable amounts present
at 4 hours post infection (Baldick et al., 1992). The viral mRNA produced
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before the second stage of uncoating are classified as early viral mRNA and
the proteins encoded by this early viral mRNA are classified as early viral
proteins. These early proteins include growth factors and immune defense
molecules as well as proteins required for the second stage of uncoating and
later DNA replication (reviewed in Moss, 1990 and Traktman, 1990). After the
second stage of uncoating, the initiation of viral DNA replication can take
place (Broyle, 1993). The viral DNA is replicated in the cytoplasm in localized
areas called factories, which become larger and more pronounced as the
infection continues.

The cytoplasmic sites of replication, as opposed to

within the nucleus, is a characteristic trait of all poxviruses and a trait that
makes them unique among viruses. The cytoplasm of the host cell is also the
site of viral assembly. Two distinct forms of infectious particles can be seen,
intracellular mature virions (IMV) and extracellular enveloped virions (EEV)
which travel to the cell surface using microfilaments (Hiller, et al., 1981) and
leave the host cell by budding out. The EEV have an additional lipoprotein
envelope, derived from the host cell membrane, when compared to IMV
(Payne, 1978). There are differences in the pathogenesis of IMV and EEV
and differences in the surface proteins of each, but both types of particles
can cause infection.
Immediately following infection and for a variable amount of time
afterwards the infected host cell cannot be differentiated from a non-infected
host cell on the basis of any observable characteristic. As a viral infection
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progresses, the changes seen in the host cell are termed the cytopathic
effect (CPE). The characteristics of the CPE that is observed during infection
is a function of the type of virion and the type of host cell infected.

Poxvirus

infection causes the host cell to change its cytoskeletal organization and
overall morphology as the infection progresses (Traktman, 1991).

The

morphological changes observed include granulation of the cytoplasm due to
the increasing viral factories and accumulating viral particles as well as the
rounding and retraction of infected cells followed by possible detachment of
infected host cells from the surface of the flask during later stages.

Yatapoxviruses

Yaba monkey virus (YMTV), tanapoxvirus (TPV) and yaba-like disease
virus (YLDV) are the members of the genus Yatapoxvirus belonging to the
family Poxviridae. Yatapoxvirus genus viruses infect all primates, but are
thought to mainly infect non-human primates. YMTV was first isolated from
tumors that occurred in a colony of monkeys is Nigeria (Niven et al., 1961).
No evidence of human infection with YMTV in nature has been reported, but
subcutaneous injection produces tumors in the skin of monkeys and human
beings (Fenner, 1996).

TPV and YMTV show minimal to moderate

serological cross reactivity.

Primates first infected with TPV and later

challenged by YMTV, showed delayed and diminished symptoms, while TPV
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and YLDV show more significant cross reactivity with TPV infection fully
protecting primates against YLDV challenge (Downie and Espana, 1973). A
mAb generated against YLDV shows cross reactivity with TPV (Haller, 2001).
Some authors (Fenner, 1996) have referred to TPV and YLDV to be the
same virus, but there is data to suggest that TPV and YLDV are separate, but
closely related strains, both distinctly different from YMTV.

The DNA

restriction maps of TPV and YLDV show only minor differences between
them while YMTV showed more significant differences when compared to
both TPV and YLDV (Knight et al., 1989).

Tanapoxvirus and Yaba-like Disease Virus

TPV was first identified in a village on the flood plains of the Tana River valley
in Kenya.

TPV was originally isolated from human skin biopsy specimens

taken during a much more widespread outbreak of disease among residents
of the Tana River Valley 1962 (Downie et al., 1971). This epidemic was
associated with flooding in Kenya when the human population, domestic
animals and the wild animal population were crowded together on small
islands among the floodwaters. Subsequent serological studies showed that
it was endemic to this area and many subsequent cases were identified
during surveillance for monkeypox in Zaire from 1977 to 1981. The majority
of the cases identified in Zaire occurred among people living in close
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proximity to the Zaire River and more frequently in people who worked close
to the river as opposed to working in the upland agricultural fields (Jezek et
al., 1985). An arthropod vector, possibly mosquitoes, is thought to be the
culprit responsible for the transmission of TPV to humans from its reservoir
among the wild animal populations.
In 1965 and 1966, animal handlers at primate centers in California,
Oregon and Texas contracted a poxvirus disease through cuts or abrasions
that happened when handling infected monkeys or cleaning cages that
housed infected monkeys (Crandell et al., 1969). The virus isolated from
these monkeys was initially shown to be indistinguishable in its serological
properties to TPV isolated in 1962 from the infected natives in Kenya (Downie
and Espana, 1971).

Isolates from these cases have been described as

"Yaba-like disease virus" and "Yaba-related virus" (Crandell et al., 1969)
because the lesions formed appear similar to those seen in YMTV. These
isolates have also been called "Oregon '1211' poxvirus"

(Nicholas and

McNulty, 1968) and "OrTeCapox virus" since the same strain appeared to
have been spread to Oregon, Texas and California carried by monkeys from
the same animal supplier.

Because the virus isolated from monkeys in

American primate centers is antigentically very similar to the TPV isolated
from humans, they have been considered a single species (Downie and
Espana, 1973, Fenner, 1996).

Further research has shown that the TPV

isolated from humans in Kenya and the virus isolated from monkeys at the
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American primate centers to be very closely related, but not identical (Knight
et al., 1989, Lee et al., 2001). For clarity, this paper will refer to isolates from
humans in the Tana River valley, Kenya as TPV and isolates from monkeys
and animal handlers at the American primate centers in 1965-1966 as Yaba
like disease virus, or YLDV.
The last known case of TPV within the United States was from a
student in New Hampshire who had recently returned to the United States
from Africa in the fall of 2002 (Dhar, et al.,). She had spent eight weeks
serving and caring for orphaned chimpanzees in the Republic of Congo.
Initially, health care professionals were greatly concerned about a potential
smallpox outbreak given the symptoms of the patient and the current
concerns of the potential use of VV as a weapon of bioterrorism. Electron
micrographs of TPV and VV appear identical, but the CDC later correctly
identified that case as a TPV infection and a clinical isolate from that
individual currently resides in the laboratory of Dr. Karim Essani.
TPV replicates in a manner similar to other poxviruses, but the
replication cycle is longer when compared to VV (Mediratta and Essani,
1999). TPV does cause disease in humans, but in contrast to smallpox, the
infection is usually self-limiting in people with competent immune systems
and a pustule is only formed at the site of infection. The initial skin lesion is a
small raised nodule that appears to be similar to what is normally seen with
an insect bite and gradually enlarges for about two weeks. The disease is
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characterized by fever, severe headache, backache and flu-like symptoms
lasting less than a week.

The lymph nodes draining the initial site of

infection are enlarged and tender from about the fifth day after the
appearance of the skin lesion which usually ulcerates during the third week
and then heals within 5 to 6 weeks leaving a scar.
Part of the genomic sequence of TPV is known (Neering, 1993). The
genomic sequences for YMTV, YLDV, VV and many other pox viruses have
also been published and are readily available enabling the study of the
homology among poxvirus encoded proteins (Lee et al., 2001, Brunetti et al.,
2003, Gubser et al., 2004).

TPV, like some other poxviruses, has been

shown to secrete immunomodulatory proteins that inhibit host immune
responses (Essani et al., 1994, Paulose et al., 1998, Smith et al., 1998, Smith
et al., 2000, Brunetti et al., 2003). Research into the structure and function of
these proteins provide an excellent opportunity to provide new information as
to the intricacies of the immune system. The relatively low risk of handling
cultures and the published genomic sequences make TPV a good model for
studying a member of the Poxviridae, the proteins that are encoded by its
genome and their role in the virus-host relationship.
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Antibodies
History of Antibodies

Since ancient times it has been known that previous exposure to certain
diseases gives the survivors protection against contracting those diseases
later in life. An infant or young child is susceptible to many infections, but
with the aid of a functioning immune system, the child will develop specific
immunity to many of the pathogens once their body has successfully dealt
with them. The immune system has memory. The survivors are still prone to
contracting many other diseases, which demonstrates another key concept of
the immune system. The immune system is specific, or in other words, there
is immunological specificity.
The blood has long been the focus of the study of immunity. In 1794,
John Hunter observed that blood did not putrefy as rapidly as other tissues.
In 1888, Nuttall observed that the serum from normal, healthy animals could
sometimes kill micro-organisms.

In 1890, von Behring and Kitasato

demonstrated that immunity to diphtheria and tetanus was attributed to
antibodies to the toxins that are produced by each of those pathogens
(reviewed in Goding, 1996).

The medical application of these findings

resulted in a wide range of outcomes. Using the serum from an immunized
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animal to treat a human or animal that had not been immunized, called
"serum therapy", sometimes lead to dramatic recovery.

In other cases it

resulted in a syndrome known as "serum sickness" with skin rashes and
arthritis the result of the development of massive amounts of antigen
antibody complexes. Occasionally sudden death due to what we now call
anaphylactic shock was the unfortunate result. Paul Ehrlic showed that there
was a quantitative relationship between the plant toxin ricin or abricin and the
amount of antibody needed to neutralize their toxicity.

To Ehrlich, this

suggested a chemical reaction between antigen and antibody. Ehrlich also
championed the notion that these chemical reactions involved specific
binding and proposed the "lock and key" analogy when referring to antigen
antibody interactions. With the scientific advancements in the area of genetic
theory, protein structure and the reconciliation of the many observations of
cellular and humeral immunity, antibodies and the B-lymphocytes that
produce them became a large focus of study on the specificity and memory
aspects of the immune system.

Monoclonal Antibodies

It is now well demonstrated that the sera of an animal is polyclonal
with each B-lymphocyte predetermined to make one and only one antibody
that recognizes a single specific complimentary antigen and at each particular
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time each clone population is some percentage of the total B-lymphocyte
population.

According to the clonal expansion theory, when an animal is

immunized with an antigen, the clonal expansion of those B-lymphocytes that
recognize the antigen and their differentiation into antibody secreting cells
takes place.

If individual antigen recognizing B-lymphocytes could be

separated and propagated continuously in vitro the culture supernatant would
contain homogeneous antibody molecules that recognize one or a few very
closely related antigens.

Unfortunately the progeny of an untransformed

lymphocyte cannot be grown continuously in vitro.

The progeny of

transformed, or immortal, B-lymphocytes can be grown continuously in vitro
producing large amounts of monoclonal antibody (mAb).

In 1975 the first

immortalized antibody secreting lymphocytes were created by fusing
immortalized

lymphocytes

with

untransformed

lymphocytes (Kohler and Milstein, 1975).

antibody

secreting

These hybrid cells whose parents

were an immortal myeloma cell and secreting B-lymphocyte are called
hybridomas.

These hybridomas can then be grown from individual cells

producing monoclonal cell lines that secrete one particular antibody molecule.
When two antibody producing cells are fused, the resulting hybridoma
cell expresses the antibodies from both parental lines, although the light and
heavy chains of both parental lines are randomly joined, showing no evidence
of scrambling of the variable or constant regions are observed.

In other

words, even though each antibody may be a mixture of polypeptides with
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some coded for by the genes for one parental line and some coded for by the
other parental line, each individual polypeptide chain was entirely coded for
by a single parental line (Cotton and Milstein, 1973).

Milstein had been

interested in the genetic control of antibody synthesis.

Cotton and Milstein

(1973) constructed hybrids between rat and mouse myeloma cells and found
that the synthesis of both species of antibody was retained, but hybrid
polypeptides that would have some amino acids coded for by rat DNA and
some coded for by mouse DNA were not seen.

These results were

consistent with the idea that the variable region and constant region joining
took place at the DNA level and not on the mRNA level. For the production of
mAb that is identical to the secretory lymphocyte, an immortalized myeloma
cell that is non-secreting would make an ideal fusion partner with the resulting
hybridoma secreting only the mAb from the lymphocyte parental line.

A

myeloma cell line, P3-X63-Ag8.653, which does not express heavy or light
chains was discovered in 1979 and was shown to be an ideal fusion partner
(Kearney et al., 1979).

Cell Fusion and Hybridoma Selection

Sendai virus was the original agent used to fuse cells to create
hybridomas. Electroporation (Steenbakkers et al., 1993) and electroacoustic
(Bardsley et al., 1990) are relatively newer techniques that may be useful
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when low numbers of B-lymphocytes are available for fusion.

The most

traditional method of fusion involves using polyethylene glycol (PEG) to fuse
the membranes of two cells together. The exact mechanism of fusion is still
poorly understood, but presumably PEG promotes close apposition of
adjacent cell membranes (Zimmerberg et al., 1993).
If a mixture of cells containing myeloma cells and secretory B cells is
treated with agents that promote fusion, the resulting fusion products are
random and poorly controlled. In addition to the myeloma-B cell hybrids that
are the desired goal, there will be many myeloma-myeloma and B cell-B cell
fusion products in addition to fusion products that result from the fusion of
several cells. Individual myeloma and B cells that did not undergo any fusion
will also be present. In order to produce a long term hybridoma cell line that
secretes mAb, a selection process is required. The most common selection
involves the blocking of nucleotide biosynthetic pathways by the careful
selection of fusion partners and by use of a selective medium. This process
was originally devised by Littlefield (1964). This selection procedure is based
on the fact that when the main biosynthetic pathway for guanosine synthesis
is blocked by the folic acid antagonist aminopterin. There is an alternate
"salvage" pathway in which the nucleotide metabolite hypoxanthine is
converted by the enzyme hypoxanthine guanine phosphoribosyl transferase
(HPRT) to guanosine monophosphate providing the essential nucleotide
despite having the main pathway blocked. Cells lacking a functional HPRT
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enzyme die in a medium containing hypoxanthine, aminopterin and thymidine
(HAT medium). HAT medium selects for HPRT(+) cells because aminopterin
blocks the main pathway.

The parental B cells will be HPRT(+) and all

combinations of fused B cells as well as non-fused B cells will not be killed by
the selective HAT medium, but because they are not transformed cells they
will only survive a few weeks at most in vitro.

All combinations involving

HPRT(-) myeloma cells, fused or un-fused, will be all be killed by HAT
medium. HPRT(-) meyloma cells can be selected for prior to the fusion by
the use of the toxic base analogs 8-azaguanine or 6-thioguanine which are
incorporated into DNA by HPRT.

Because the salvage pathway is not

normally essential for survival, mutants that lack HPRT +will continue growing
while HPRT(+) cells will die. Only the fusion products involving the immortal
myeloma cells and the HPRT(+) B cells will survive indefinitely in HAT
medium. The resulting HPRT+ hybridomas can be cloned by limited dilution
to create uniform cultures that produce mAb. Selection for HPRT(-) myeloma
cells prior to fusion is essential due to the fact that myeloma cells will
spontaneously mutate back to HPRT(+) cells (Littlefield 1964 ). Enough time
must be allowed to clear the medium that the HPRT(-) myeloma cells are
grown in of 8-azaguanine because it is toxic to the HPRT(+) hybridomas
which will be produced later.
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Impact of Monoclonal Antibodies

Monoclonal antibodies (mAbs) have had revolutionary consequences
in biological research and clinical medicine and has resulted in an industry
that has an economic impact measured in billions of dollars (Chien and
Silverstein, 1993). The specific binding properties of mAbs make them a
useful research tool for the identification and analysis of proteins (Singh et al.
2003 and Tanimura et al., 2004).

The genetic revolution has had an

extremely profound effect on biological research and its applications, but all
the information contained in any gene sequence is in most cases only
relevant once it is expressed as protein. DNA has proved to be the blueprint
of life, but proteins are still the structure and functional machines of life. One
reason the notion that nucleic acids were the molecules conveying heredity
was so elusive was because so much focus was placed on proteins. Proteins
are literally found everywhere and do everything in biological systems. Even
though the amino acid sequence of a multitude of genes are literally a mouse
click and a BLAST search away, this information is greatly complicated by
post-translational modifications, protein folding and three dimensional
structure.

A gene sequence is not the end of biological research on the

function and effects of that gene, it is often just the beginning. The specificity
of mAb technology provides a means to identify and/or purify a single protein
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out of a complex mixture of molecules.

They can be used to identify and

study novel proteins of micro-organism or macro-organism origin, greatly
aiding the advancement of basic scientific research which is the backbone of
literally all technological advances. The use of mAbs in the generation of
enzyme linked immunosorbent assays (ELISAs) has dramatically improved
the quality and efficiency of many standardized tests and clinical diagnostic
assays.

mAbs conjugated with a radioactive, or fluorescent label can be

used to not only detect the presence of a protein, but the location as well.
The indirect immunofluorescence images presented later in this manuscript
were made using this technique.

Using the specificity of mAbs to target

cancer cells has had its successes as well as failures, but continues to be an
area of intense research. The net effects resulting from the generation of a
novel mAb is unknown, but it would no doubt be a welcome addition to the
legacy of mAb technology.
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MATERIALS AND METHODS

Virus, Cells, Reagents and Animals
Owl monkey kidney (OMK) cells obtained from the American Type
Culture Collection (ATCC, Rockville MD) were grown in the growth medium
defined as: EMEM with 10% (v/v) newborn calf serum (NBCS), 0.2 mM L
glutamine and antibiotics (100units/ml penicillin G sodium, 100 µg/ml
streptomycin sulphate and 0.25 µg/ml amphotericin B). Infected and mock
infected OMK cells were maintained in the maintenance medium that
contained 2% (v/v) NBCS instead of the 10% in the growth medium. TPV was
cultivated in OMK monolayers as described later. Mouse myeloma cells,
P3x63.Ag8.653 (ATCC) cells were grown in RPMI 1640 supplemented with
10o/o(v/v) FBS, 0.2 mM L-glutamine and antibiotics. All myeloma, hybridoma
and OMK cells were incubated at 37 °C and 5% CO2.

All tissue culture

media, sera and reagents were purchased through Sigma (St. Louis, MO).
Six BALB/c female mice, 4-6 six week old (Charles River laboratories,
Portage Ml) were kept at the animal facility in Haenicke Hall at Western
Michigan University. All animals were monitored and treated in accordance
with the approved IUCUC protocol number 03-01-01.
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Virus Cultivation

Confluent monolayers of OMK were infected with either purified TPV
(ATCC), or a mixture of TPV and cellular debris- from previously TPV infected
OMK cells. After adsorption at room temperature (unless otherwise stated)
for 90 minutes. The infected preparations were incubated in maintenance
medium at 37 ° C and 5% CO2 for 10-14 days. Infected cells from monolayers
showing advanced CPE were harvested using a sterile cell scraper and
collected as a 1X virus preparation.

Virus Quantification

Quantification of viral preparations were performed by viral plaque
assay (E.ssani, 1982).

Confluent OMK monolayers grown in 6-well plates

were infected with 200.0 µI per well of serial ten-fold dilutions of the viral prep.
Each dilution was plated in duplicate. The series of 6-well plates were placed
on a rocker table for virus adsorption at room temperature for 90 minutes.
Following adsorption, 3.0 ml of maintenance medium with 0.5% methyl
cellulose (4000 centipoises) (overlay medium) was carefully added to each
well. The infected preparations were incubated at 37 ° C and 5% CO2 for 1014 days. The overlay medium was then aspirated from each well and 1.0 ml
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of 0.1% crystal violet and 10% formaldehyde in deionized water was then
added to each well to fix and stain the cells. The stain was removed and the
plates were rinsed with distilled water and allowed to dry. The number of
plaques in each well were counted. The average number of plaques for each
dilution were calculated and multiplied by the dilution factor to calculate the
plaque forming units (pfu) per ml of the original preparation.

Preparation of Monoclonal Antibodies

Preparation of lnnoculum and Immunization of Mice

Four confluent monolayers of OMK cells (3 x 105) in 35 mm dishes
were infected with TPV (10 pfu/cell).

Once all of the OMK cells showed

uniform CPE (4-5 days), the infected cell monolayers were washed three
times with phosphate buffered saline (PBS). Sterile deionized water (200.0
µI) was added to each dish and the attached cells were scraped with a cell
scraper to suspend the cells. The contents of each dish was collected and
pooled and sterile dionized water was added to a total volume of 1.5 ml and
stored at
-20 ° C. Six BALB/c female mice were immunized by a series of five weekly
intraperitoneal injections of 100.0 µI of the prepared innoculum as described
in Current Protocols in Immunology (Coligan, et al., 1996). No adjuvants of
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any kind were used. A final booster injection was given three days prior to
fusion. All animals were monitored and treated accordance with the approved
IUCUC protocol number 03-01-01.

Preparation of Myeloma Cells and Feeder Layers

Two weeks prior to fusion the myeloma cells were grown in medium
2

supplemented with 6.6x10- M 8-Azaguaninine (Sigma) to kill any HPRT(+)
revertants.

After 2-3 cycles in medium containing 8-Azaguaninine, the

myeloma cells were grown in normal medium without 8-Azaguaninine for 2-3
cycles. The cells were propagated in fresh growth medium one day prior to
the fusion to ensure that the cells were in the exponential growth phase. The
live myeloma cells were counted using a hemocytometer and trypan blue to
ensure a 1: 1 ratio of immunized splenocytes to myeloma cells (Freshney,
1994 ).

8

Each mouse spleen was estimated to have 1 x 10 splenocytes

(Coligan et al., 1996). Twenty four hours prior to fusion, "feeder cells" were
obtained from a non-immunized female BALB/c mouse. The mouse was
sacrificed by cervical dislocation and 1.0 ml of PBS was injected
intraperitoneally and then the abdomen was massaged. After rinsing with
70% ethanol, the peritoneal cavity was opened with sterilized scissors. A
sterile, cotton plugged, glass pipette was used to remove the PBS containing
the feeder cells and added to a centrifuge tube with 50.0 ml of hybridoma
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growth medium.

The peritoneal cavity was washed with this solution to

remove as many cells as possible. Care was taken to avoid scraping the
walls of the cavity in an attempt to minimize the number of fibroblasts
collected. 100.0 µI of this feeder cell preparation was distributed to each well
of five flat-bottom tissue culture plates using a multichannel pipette.

The

feeder cell plates were incubated overnight at 37°C and 5% CO2.

Fusion

An immunized female BALB/c mouse was sacrificed by cervical
dislocation and rinsed with 70% ethanol.

The spleen was removed and

transferred to a 50.0 ml centrifuge tube containing 5.0 ml of 37 °C serum free
medium (supplemented with antibiotics only). The spleen was then placed on
a sterile, stainless steel mesh on top of a glass beaker in a laminar flow hood.
A rubber policeman was used to homogenize the spleen. The spleen cells
were washed with additional serum free medium. The contents of a prepared
flask of myeloma cells was added to this mixture and centrifuged (75xg
Damon IEC HN-SII, 1500 rpm) for 10 minutes.

The supernatant was

removed and the pellet was gently resuspended in serum free medium. The
splenocyte/myeloma cell mixture was washed in this manner two more times
in an attempt to remove FBS proteins from this mixture. Following the third
wash, the supernatant was removed l�aving approximately 100.0 µI of serum
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free medium to resuspend the pellet. A beaker containing 37 ° C water was
placed in the laminar flow hood and the tube was placed in it to stabilize the
temperature.

1.0 ml of polyethlyene glycol (PEG) was added to the

resuspended cells over the course of 1 minute. A controlled 1 :50 dilution of
the PEG and suspended cell mixture with serum free medium was carried out
as follows: 10.0 ml over 10 minutes; 10.0 ml over 5 minutes; 10.0 ml over 3
minutes; 10.0 ml over 2 minutes; 9.0 ml over the last 1 minute. This mixture
was then centrifuged (75xg Damon IEC HN-SII, 1500 rpm) at room
temperature for 10 minutes. The supernatant was discarded and the pellet
resuspended in 50.0 ml of hybridoma growth medium. 100.0 µI of this fusion
preparation was added to each well of the 96-well feeder plates using large
bore pipette tips (BIO-RAD, Richmond, CA, catalog number 223-9312) to
reduce the physical stress on the freshly fused cells. These plates were
incubated overnight at 37 ° C and 5% CO2. Following incubation, 100.0 µI of
4

hybridoma growth medium supplemented with 2x10- M hypoxanthine, 8x10-7
M aminopterin and 3.2x10-5 M thymidine (HAT) (2X selection medium) was
added to each well to select for HPRT(+) cells. Three days after the addition
of HAT medium, 100.0 µI of supernatant was removed from each well and
replaced with 1X HAT medium to decrease the amount of dead cell
byproducts in each well. After seven days all media changes were done with
4

hybridoma growth medium supplemented with 2 x 10- M hypoxanthine and
3.2x10-5 M thymidine (HT) only.
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Initial Screening

Confluent OMK monolayers were grown in 96 well plates and half of
the plates were infected as described earlier. Infected and uninfected plates
were kept in maintenance medium until 95% of the cells demonstrated CPE.
The maintenance medium was removed and 100% ethanol at -80° C was
added to each plate for 30 seconds to fix the cells.

The ethanol was

aspirated and the cells were washed with PBS with 0.1% gelatin (BIO-RAD,
Richmond, CA) to block any non-specific protein binding. 100.0 µI of 1X
hybridoma supernatant from wells to be tested was added to wells in both the
infected and uninfected plates and incubated at room temperature for 4
hours.

The supernatant was aspirated and the wells were washed three

times with PBS with 0.1% gelatin. The secondary antibody, anti-mouse lgG
alkaline phosphatase conjugate developed in goat (Sigma) was diluted
3:5000 in PBS with 0.1% gelatin and 50.0 µI was added to each well and
incubated at room temperature for 4 hours. Each well was washed with PBS
with 0.01% tween 20 to remove any unbound secondary antibody. 100.0 µI
of p-nitrophenyl phosphate (PNP) substrate (AGDIA, Elkhart, IN) was added
to each well and the plates were read on a microplate reader (El 800, Bio
Tek, Winooski, VT).

The absorbance due to the accumulation of product
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was recorded for each well and the difference between the uninfected and
infected was calculated.

lsotyping

Supernatant from hybridoma clones that gave positive ELISA results
were concentrated using a Micon 8-15 Clinical Sample Concentrator
(Millipore, Bedford MA). A glass pasture pipette was used to add 5.0 ml of
hybridoma supernatant to a chamber of the 8-15 and allowed to decrease in
volume to a concentration of �25X. Ouchterlony double diffusion technique
was used to determine the heavy chain isotype of all antibodies that
produced positive ELISA results. A 1 % (w/v) solution of agar in deionized
water was heated in a microwave oven, plated on a glass slide and allowed to
cool and form an agar slab. Wells were punched in the agar slab with one
central well and several surrounding wells equidistant from the center well.
Reagents from a monoclonal antibody isotyping kit (Sigma) were used with
25.0 µI of an anti-isotype stock placed in the center well with 25.0 µI of 20X
concentrated supernatant was added to the outer wells. Slides were made
with different anti-isotype reagents: anti-mouse lgG1, anti-mouse lgG2a, anti
mouse lgG2b, anti-mouse lgG3, anti-mouse lgA and anti-mouse lgM. After
the initial reagents diffused into the agar, 10.0 µI of PBS was added to each
well. The slides were placed in a humidified incubator overnight at 37 ° C.
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Following incubation the slides were placed in room temperature PBS for 48
hours, with several changes of PBS to elute all non-conjugated protein. Each
slide was covered with moistened filter paper and placed in a 37° C incubator
without humidification to dry completely overnight.

Once the agar had

completely dried, the slides were stained with a 0.1 % Coomassie blue
solution. Following staining the slide was rinsed with deionized water and
placed in destaining solution (5% (v/v) methanol, 7% (v/v) glacial acetic acid
in deionized water) for 48 hours with several changes in destaining solution.

Indirect lmmunofluorescence (IF) Assay

OMK monolayers were grown in 35mm dishes on sterilized glass cover
slips (Corning, New York). Half of the cover slips were infected with TPV as
described and kept in maintenance medium until 95% of the cells
demonstrated CPE.

The maintenance medium was removed and 100%

ethanol at -80° C was added to each dish for 30 seconds to fix the cells. The
ethanol was aspirated and the cells were washed with PBS with 0.1 % gelatin
(BIO-RAD) to block any non-specific protein binding.

An uninfected and

infected coverslip was covered with 1 ml of 1 X hybridoma supernatant and
placed in a 37° C humidified incubator for 2 hours. The supernatant was
aspirated and the coverslips were washed three times with PBS with 0.1 %
gelatin. The secondary antibody, anti-mouse lgG fluroescein isothiocyanate
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(FITC) conjugate developed in goat (Sigma) was diluted 1: 100 in PBS with
0.1% gelatin and then added to each cover slip and incubated in a 37 ° C
humidified incubator for 2 hours. Each cover slip was washed with PBS with
0.1% gelatin to remove any unbound secondary antibody. Each cover slip
was mounted on a glass slide with 20% glycerol and sealed with "Nailslicks"
(Cover Girl, Hunt Valley, MD).

Slides were then viewed on Nikon

MICROPHOT-FXA (Nikon, Tokyo, Japan) as phase contrast images and
indirect fluorescent (IF) images. For the IF images, the excitation filter set to
450-490 nm and barrier filter set to 520 nm using a super high pressure
mercury lamp (model HB-10101AF, Nikon).

SOS-PAGE

Two confluent OMK monolayers in 35 mm dishes were infected with
concentrated TPV at a multiplicity of infection (110 pfu/ml). These two dishes
along with a mock infected dish were placed on a rocker and adsorption was
allowed to take place at 4 ° C for 90 minutes.

After adsorption 2.0 ml of

maintenance medium was added to each dish and cytosine arabinoside (Ara
3
C) was added to a final concentration of 10- M to one of the virus infected

preparations. All preparations were incubated at 37° C and 5% CO2 for 72
hours. At 72 hours post infection the medium was removed and the cells
were washed with 4 ° C PBS. 100.0 µI of 1% (v/v) Nonidet 40 (NP40) and
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100.0 µI of 2X dissociation buffer

(0.125M Tris HCI pH 6.8, 4.6% (w/v)

sodium dedecyl sulphate (SOS), 20% (w/v) glycerol, 10% p-mercaptoethanol
(ME) and 0.002% bromophenol blue). Each preparation was collected in an
Eppendorf centrifuge tube and repeatedly pipetted up and down with a
hamilton syringe to physically break up the- strands of DNA until the
preparation was less viscous. Immediately prior to loading, each sample was
heated to 100°C for 3 minutes to solubilize all proteins.

Twenty µI of each

sample along with 5.0 µI of Seeblue protein standard (lnvitrogen, Carlsbad,
CA) was loaded into a 12% Tris-Glycine gel and ran at 125 volts in an Xcell 11
mini-cell (Novex, San Diego, CA) for approximately one hour.

Western Blot

After approximately one hour the gel was removed from its cast and
transferred to a nitrocellulose membrane using 4°C transfer buffer (running
buffer 0.025M Tris-base, 0.192 M glycine, 0.1% (w/v) SOS and 30% (v/v)
methanol) and a Trans-Blot SD (BIO-RAD) semi-dry transfer cell.

The

system was set for one hour at a constant' 12 volts. The Western blot was
then place in 4°C blocking buffer [Tris buffered saline (TBS) with 5% (w/v)
nonfat dry milk (Carnation)] and rocked for 50 minutes at room temperature.
The blocking buffer was removed from each blot and 2.0 ml of the
appropriate hybridoma supernatant (1x) was added to the blot and sealed in
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a kepex bag. Each bag was rocked at room temperature for 50 minutes and
stored at 4 ° C overnight. Each blot was placed in a dish on an orbital shaker
and washed for six, approximately 10 minute stages in washing buffer (TBS
w/ 0.01% (v/v) tween 20, pH 7.6). Five µI of secondary antibody, anti-mouse
lgG peroxidase conjugate developed in goat (Sigma) was added to 2.0 ml of
blocking buffer and placed with the blots in clean microscope slide dishes on
the orbital shaker for 90 minutes at room temperature.

Each blot was

removed and placed in a dish on an orbital shaker and washed for six
approximately 10 minute stages in washing buffer as before.

The o

Phenylenediaimine (OPD) (Sigma) substrate was prepared by adding 6.1 ml
0.1 M citric acid, 6.4 ml sodium phosphate, 12.5 ml deionized water and 10.0
µg OPD. Ten µI of 30% (v/v) hydrogen peroxide was added once the OPD
was completely dissolved. 3.0 ml of substrate was added to each blot in a
darkened room and a digital picture was taken once bands became visible
(approximately 5 minutes).

Neutralization Assay

Two volumes of 1x hybridoma supernatant (200.0 µI) were mixed with
one volume (100.0 µI) of a 1: 100 dilution of supernatant from TPV infected
OMK cells. Hybridoma growth medium was added in place of the hybridoma
supernatant (200.0 µI) to 100.0 µI of a 1:100 dilution of supernatant from TPV
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infected OMK cells as a control. This mixture was incubated at 37 ° C for 2
hours and 100.0 µI of this mixture was added to a well of a six well dish with
confluent OMK monolayers in duplicate.

After adsorption at room

temperature for 90 minutes, the innoculum was removed and 3.0 ml of
overlay medium (maintenance medium with 0.5% (w/v) methyl cellulose) was
carefully added. The plates were incubated for 10 days at 37 ° C and 5%
CO2. The overlay medium was then aspirated from each well and 1ml of
0.1% crystal violet staining solution was added to fix and stain the cells. After
5 minutes the plates were rinsed with water and allowed to dry.

Plaques

were counted and the average for the wells was used to calculate plaque
forming units (pfu)/ml as described by Essani and Dales (1979).

Cloning by Limited Dilution

All hybridoma clones that produced positive ELISA screening results
were cloned to ensure the presence of only one clone and decrease the
chances of propagating non-producing clones.

Positive clones were

suspended through pipetting and plated out in serial twofold dilutions with
hybridoma growth medium. The group in which about half the wells had no
growth was considered to be the progeny of single cells and were rescreened
for antibody production (Coligan et al., 1996).
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Cryopreservation of Hybridoma Cells

2

Positive hybridoma clones were grown in 25 cm tissue culture flasks
in hybridoma growth medium. Each flask to be frozen was fed the day before
freezing to ensure the cells were in exponential growth phase. The cells were
resupended by pipetting and transferred to a 15.0 ml conical centrifuge tube
and centrifuged (75g Damon IEC HN-SII, 1500 rpm) at room temperature for
2 minutes. The supernatant was removed and replaced with FBS with 8%
(v/v) sterile dimethyl sulfoxide (DMSO) (freezing medium). The cells were
then placed in freezing vials and placed in a freezing container to achieve a 1° C/min rate of cooling and stored in a -80° C freezer for 24 hours. Following
this 24 hour period the cells were immediately transferred into liquid nitrogen
for cryopreservation. One week after cryopreservation, one vial was removed
from the liquid nitrogen an.d immediately placed in a 37° C water bath. The
thawed cells were diluted 1 :20 with hybridoma growth medium in a 25 cm
flask and incubated at 37° C and 5% CO2 to check for viability.

2
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RESULTS

Development of Monoclonal Antibodies Directed Against Tanapoxvirus

Modifications to the technique developed by Kohler and Milstein
(1975) as described by Haller (2001) were used to develop hybridoma clones
that produce mAbs directed against TPV encoded proteins. Over 3000 wells
were initially screened by ELISA. Over the course of three years six fusions
were carried out with widely varying results. The first two fusions produced
relatively few viable clones and no clones that produced positive results by
ELISA were able to be cultivated. The third fusion produced three clones that
produced positive ELISA results and were able to be cultivated in 25 cm2
flasks, but these clones were determined to be of the lgM isotype and
deemed of little interest.

The next two fusions produced eight clones that
2

produced positive ELISA results and were able to be cultivated in 25 cm

flasks, but despite attempts at cloning by limited dilution every culture
eventually became non-producing and produced negative ELISA results. The
sixth fusion was by far the most productive yielding a dramatic increase in the
number of viable clones. Seven clones that produced positive ELISA results
2

were cultivated in 25 cm flasks with six clones being characterized. The six
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clones were labeled 1C11, 2G1, 2G3, 3A10, 4A4 and 5A11. The ratio of
immunized splenocytes to myeloma cells for the sixth fusion was 1:1,
whereas the ratios from the other fusions ranged from 8:1 to 5:1.
Established flasks of hybridomas were periodically verified by the original
ELISA procedure to ensure antibody production and to guard against the
propagation of non-producing clones. Cryopreservation of hybridomas using
hybridoma growth medium supplemented with 10-30% DMSO had limited
success. Hybridoma viability after removal from liquid nitrogen was slightly
improved by diluting the contents of the cryovial 1:20 with hybridoma growth
medium and then centrifugation followed by discarding the supernatant and
resupending of the pellet in hybridoma growth medium prior to incubation.
Residual DMSO from the freezing medium has been reported to have a
higher toxicity to murine myeloma cells compared to most cell lines
(Freshney, 1994).

Hybridoma growth medium supplemented with 10-50%

glycerol was also tried with better results.

Optimal results for the

cryopreservation and retrieval of antibody producing hybridoma cells was
obtained by using hybridoma tested FBS (Sigma) with 8% (v/v) DMSO as a
freezing medium.
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lsotype Characterization of Monoclonal Antibodies

Ouchterlony double diffusion assay was used to determine the isotype of
each of the hybridoma clones. A summary of the results is compiled in Table
1.
Table 1.
lsotypes of TPV-Specific Monoclonal Antibodies
Monoclonal antibodies
1C11
2G1
2G3
3A10
4A4
5A11

lsotype
lgG2a
lgG1
lgG1
lgG1
lgG1
lgG1

lsotypes were determined by the Ouchterlony double diffusion method using reagents from a
Sigma isotyping kit.

Indirect lmmunofluorescence (IF) Assay

All clones that tested positive in the initial ELISA screening
demonstrated binding of mAb to TPV infected OMK cells through IF asssays.
PBS with 0.1 % gelatin was used for each washing cycle.

PBS with 0.01 %

tween was tried as a washing agent, but it resulted in a much higher
background level. The IF images show mAb binding in localized areas of the
cytoplasm of TPV infected cells (Figures 1a and 1b). These areas of intense
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FITC staining indicate the location of "Viral factories", a term used by Fenner
(1996) to describe the centers of viral replication in the cytoplasm of poxvirus
infected cells. Phase Contrast (PC) images corresponding to each IF image
clearly show the borders of all cells for reference.

Indirect fluorescence

images of uninfected OMK cells treated with hybridoma mAb and the anti
mouse lgG FITC conjugate were indistinguishable from uninfected and
infected OMK cells treated with anti-mouse lgG FITC conjugate only.
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Figure 1a.
Indirect lmmunofluorescence Microscopy Demonstrating Monoclonal Antibody Binding to TPV
Proteins in Infected Cells. OMK cell monolayers were infected with TPV and ethanol fixed, or
mock infected and ethanol fixed. All monolayers were treated with murine hybridoma
supernatant, washed and then treated with anti-mouse lgG FITC conjugate. Phase contrast
(PC) and Indirect lmmunofluorescence (IF) images were taken of each. Each row consists of
images taken of monolayers treated with the same hybridoma supernatant. The rows are
designated as A; 1C11, B; 2G1, C; 2G3. Bar= 50mm
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Figure 1b.
Indirect lmmunofluorescence Microscopy Demonstrating Monoclonal Antibody Binding to TPV
Proteins in Infected Cells. OMK cell monolayers were infected with TPV and ethanol fixed, or
mock infected and ethanol fixed. All monolayers were treated with murine hybridoma
supernatant, washed and then treated with anti-mouse lgG FITC conjugate. Phase contrast
(PC) and Indirect lmmunofluorescence (IF) images were taken of each. Each row consists of
images taken of monolayers treated with the same hybridoma supernatant. The rows are
designated as D; 3A10, E; 4A4, F; SA11. Bar = 50mm
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2G 1, 2G3, 3A 10, 4A4 and 5A 11 mAbs Bind to Late Viral Proteins

Poxvirus infection causes the production of viral proteins by the host cell that
differ in the time of their initial production and level of their production over
the course of the infection (Moss, 1996).

By comparing mAb binding to

proteins from TPV infected OMK cells versus binding to proteins from
uninfected OMK cells the specificity of mAb to viral proteins can be
determined.

By comparing mAb binding to proteins from TPV infected OMK

cells versus binding to proteins from TPV infected OMK cells that have been
treated with inhibitor of DNA synthesis, Ara-C, the viral induced protein of
interest can be characterized as an early or late viral protein.

If binding

occurs only to proteins from TPV infected OMK cells that have not been
treated with Ara-C, that protein would be considered a late protein because
DNA synthesis is required for the production of that protein. If binding only
occurs to proteins from TPV infected OMK cells treated with Ara-C, that
· protein would be considered a late protein.

If binding occurs to the same

protein from TPV infected OMK cells regardless if treatment with Ara-C
occurred of not, that protein would be considered constitutively expressed
throughout infection.
Proteins from uninfected OMK cells, TPV infected OMK cells and Ara
C treated OMK cells infected with TPV were separated by SOS PAGE and
then transferred to a nitrocellulose membrane, creating a western blot. mAb
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binding was identified by ELISA. Hybridoma clones 2G1, 2G3, 3A10, 4A4
and 5A11 all demonstrated binding to late viral proteins with 2G1, 2G3 and
5A11 showing binding to two separate late proteins (figure 2.). The apparent
molecular mass of the proteins bound by each mAb was estimated by the
method established by Laemmli (1970).

Hybr:idoma clone 1C11 did not

demonstrate any observable specific binding despite numerous positive
screening ELISA results with anti-mouse alkaline phosphate conjugate
(Sigma) as the secondary antibody (Table 2.).

Table 2.
Monoclonal Antibodies and the Viral Polypeptides They Recognize
Monoclonal
Antibody
1C11
2G1
2G3
3A10
4A4
5A11

Apparent Molecular Mass

*
16kDa 28kDa
21kDa 30kDa
18kDa
38kDa
12kDa 36kDa

* Monoclonal antibody 1C11 reacted in immunofluorescence reactions with TPV infected
cells, but not with mock infected cells (see figure 1 a).
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a b c d

a b c d

a b c d

a b c d

Figure 2.
Western Blot Demonstrating Monoclonal Antibody Binding to Late TPV Proteins. OMK cell
monolayers were either mock infected, infected with TPV and treated with Ara-C, or infected
with TPV. Cells were harvested and plasma membranes lysed with NP-40 and dissociation
buffer. Sample were loaded into SOS PAGE as follows: (a) Seeblue protein standard with
molecule masses of 250, 148, 98, 64, 50, 36, 22, 16, 6 and 4 kDa (b) mock infected OMK (c)
TPV infected OMK with Ara-C (d) TPV infected OMK. The proteins in the gel were then
transferred to a nitrocellulose membrane creating a western blot. The blots were treated with
hybridoma supernatant as follows: (A) 2G1 (B) 2G3 (C) 3A10 (D) 4A4 (E) 5A11. The western
blots were then treated with anti-mouse lgG peroxidase conjugate and exposed to the OPD
substrate. Arrows were added to the right of each image to indicate the bands of precipitate
that were formed.
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Neutralization Assay

If a mAb binds to a structural protein on the surface of a virion, viral
attachment to the host cell may be inhibited. Supernatant from TPV infected
OMK cells was mixed supernatant from each hybridoma clone and compared
to the supernatant from TPV infected OMK cells mixed with hybridoma
growth medium. If a mAb demonstrates neutralization activity, the number of
plaques formed would be decreased relative to the control.

Hybridoma

clones 2G1 and SA11 show neutralization activity. The other clones show
either slight, or no reduction in pfu/ml (Table 3.). This data is preliminary and
the sample size consisted of only two groups, therefore the results are not
valid in statistical terms.
Table 3.
Neutralization Assays
Antibody
1C11
2G1
2G3
3A10
4A4
5A11

Titer ( ofu/ml}
with
without
antibody
antibody
840 ± 0
780 ± 150
840 ± 0
645 ± 45
840 ± 0
870 ± 30
840 ± 0
780 ± 30
840 ± 0
870 ± 30
525 ± 15
840 ± 0

% Reduction
7
23
0
7
0
38

Two volumes of 1x hybridoma supernatant (200 µI) were mixed with one volume (100µ1) of a
1: 100 dilution of supernatant from TPV infected OMK cells, incubated at 37 ° C for 2 hours,
and 100 µI of this mixture was absorbed on OMK monolayers in duplicate. Controls were
treated in an identical manner, except that growth medium replaced hybridoma supernatant.
Virus titer was computed as described by Essani and Dales (1970).
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DISCUSSION

The results of this project show five mAbs that bind late viral induced
protein. The importance of cloning by limited dilution to isolate and maintain
selected

hybridomas as a culture that

produces mAb cannot be

overestimated. A quote from James Goding explains this very well:
Hybridoma lines should be cloned at least twice to make absolutely
certain that each is a true clone because the Poison distribution
specifies only probabilities not certainties ... Repeated subcloning is
also important because of the relatively high probability of growth of
nonproducer variants owing to chromosome loss. After two cycles of
cloning, the rate of chromosome loss is small, although the risk of
overgrowth by nonproducer cell is never completely eliminated.
The speed at which a nonproducing variant can overtake a culture was
demonstrated by the absence from the data presented here of the seventh
2

clone, 1 H6, that was repeatedly screened by ELISA and grown into 75cm

flasks. Hybridoma clone 1 H6 was cloned by limited dilution, and a well with
one small colony that tested positive by ELISA was propagated into several
flasks.

Once the flasks propagated from this single colony reached an

acceptable cell density the original flasks from which the cells were cloned
were discarded in favor of the flasks that had a higher probability of
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containing a single clone.

Two weeks later, each of these flasks either

screened negatively, or weekly positive by ELISA during a periodic check of
cultures. Isolation of an antibody producing clone from this mixture has not
been accomplished at the time of writing this manuscript.

It has been

suggested that nonproducing hybridoma clones can devote all of their
metabolic energy towards cell division, whereas the antibody secreting clones
devote much of their energy towards making antibodies and divide at a much
slower rate.
Hybrid9ma clone 1C11 did not demonstrate any specific binding to any
specific viral protein, early or late despite numerous positive screening ELISA
results with anti-mouse alkaline phosphate conjugate (Sigma) as the
secondary antibody. Clone 1C11 also consistently demonstrated the most
prominent precipitate during the Ouchtolony double diffusion assays of all
clones tested indicating copious amounts of antibody produced.

One

explanation for this is that the epitope that mAb 1C11 recognizes in the
screening ELISA is disrupted by the denaturing environment within the gel
during SOS PAGE.

This could be tested by immunoprecipitation of viral

antigen by Hybridoma 1C11 supernatant prior to electrophoresis.
Hybridoma clones 4A4 and 3A10 each demonstrated binding to a
single late viral protein, while clones 2G1, 2G3 and 5A11 each demonstrated
mAb binding to two distinct late viral proteins.

A mAb generated against

YLDV and showing cross reactivity to TPV has also demonstrated binding to
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two separate proteins when the immunoprecipitates created by mixing YLOV
infected cells with concentrated mAb were separated by gel electrophoresis
(Haller, 2001 ). The presence of two bands being bound by mAb could be
explained by possible cleavage of a precursor protein, with both the precursor
and cleaved proteins containing the same epitope and thus being recognized
by the same mAb. This theory could be tested by comparing mAb binding to
several samples of protein from TPV infected cells collected at sequential
post infection intervals separated by SOS PAGE and transferred to a western
blot.

A pulse-chase experiment supports this theory.

In this experiment

infected OMK cells are exposed to radioactively labeled methionine 24 hours
after infection for one hour and then all radioactively labeled methionine that
have not been taken up by the infected cells are removed. This is the pulse
part of the experiment. Cells are harvested from sequential time periods post
pulse and the proteins were separated through SOS PAGE. The change in
the profile of the proteins produced by the virally infected cells can be
observed over time.

The results show many bands are consistently

expressed over the course of infection, while some bands decreased over
time and some bands increased, or made their first appearance in time
periods after the pulse. Since no new radioactive amino acids are available
to be incorporated into newly generated proteins, the changes can be
attributed to cleavage of existing radioactive proteins explaining the
disappearance of other bands.

Monoclonal antibody 2G3 bound to two
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proteins with the apparent molecular masses of 21 kDa and 30 kDa and there
are two proteins of approximately corresponding masses that show changes
over time in the pulse-chase experiment [Figure 3., (a) and (c)]. mAb 2G1
bound two proteins with the apparent molecular masses of 16 kDa and 28
kDa. A protein of approximately (BIO-RAD, Richmond, CA) 28 kDa shows a
change over time in the pulse-chase experiment [(figure 3., (b)], but a protein
of 16 kDa would have been run off the gel used in the pulse-chase
experiment presented here. mAb SA11 binds proteins of apparent molecular
masses of 12 kDa and 36 kDa. A protein of 12 kDa would not be contained
in the gel used in the pulse-chase experiment, but several proteins around
the approximate mass of 36 kDa show a change over time in the pulse-chase
experiment [figure 3., (d)]. A protein of 12 kDa would be run off the gel used
in this pulse-chase experiment. Other published pulse-chase experiments
done with vaccinia virus have shown that several late vaccinia virus proteins
undergo cleavage and processing.

Some of these late proteins that are

processed have been shown to be major structural proteins. No processing
of early vaccina virus proteins was identified (Moss and Rosenblum, 1973).
The data from the pulse-chase experiment shows a correlation with the
results obtained, but further verification is necessary.
There are many potential uses for these antibodies. Clinical use in the
diagnosis of TPV is possible. There are many possible applications for these
antibodies as basic research tools for the study of TPV and possibly YLDV.
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The study of the structure and function of the viral proteins that are bound by
these mAbs can be greatly accelerated due to the creation of these
Hybridomas.

One particularly exciting possibility is the mAb secreted by

hybridoma 4A4 which binds a TPV protein with an apparent molecular mass
of 30 kDa. A TPV encoded secreted protein with a molecular mass of 30
kDa, which acts as an inhibitor of human tumor necrosis factor has been
reported (Brunetti et al., 2003). The mAbs generated by this project may help
elucidate the mechanisms of virus-host interactions and possibly the
intricacies of the human immune system.
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Figure 3.
Post-translational Cleavage of TPV Proteins. The samples in the lanes are described as
follows: (A) uninfected OMK cells, (B) infected OMK cells pulsed 18hrs hours post infection
(hpi) for one hour (C) infected OMK cells at 72 hrs hpi (chase period), (D) TPV isolated at 72
hrs, (E) uninfected OMK cells, (F) same as B, (G-K) infected OMK cells chased every 6 hrs
after pulse. Each arrow designates a protein that changes in concentration over the chase
period that correlates to the apparent molecular mass of a TPV protein identified by mAb
binding. The approximate molecular mass of each recognized protein is listed as follows:
2G3, 21 kDa and 30 kDa; 2G1, 28 kDa; 5A11, 36 kDa
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